$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022007717 Filed on March 29, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.623M	$9.820M	$3.485M
YoY Change	-24.73%	-37.04%	-22.21%
% of Gross Profit
Research & Development	$4.715M	$17.17M	$3.690M
YoY Change	27.78%	19.3%	-55.81%
% of Gross Profit
Depreciation & Amortization	$102.0K	$374.0K	$37.00K
YoY Change	175.68%	10.32%	-26.0%
% of Gross Profit
Operating Expenses	$7.338M	$17.17M	$7.177M
YoY Change	2.24%	19.3%	-44.06%
Operating Profit		-$26.99M
YoY Change		39.84%
Interest Expense	-$338.0K	$1.282M	-$4.000K
YoY Change	8350.0%		-102.35%
% of Operating Profit
Other Income/Expense, Net	-$103.0K	-$1.316M	-$181.0K
YoY Change	-43.09%	-1562.22%	352.5%
Pretax Income	-$7.779M	-$28.30M	-$7.362M
YoY Change	5.66%	-22.26%	-42.03%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$28.30M	-$28.30M	-$7.362M
YoY Change	284.43%	47.34%	-42.03%
Net Earnings / Revenue
Basic Earnings Per Share		-$7.47
Diluted Earnings Per Share	-$1.121M	-$7.47	-$5.812M
COMMON SHARES
Basic Shares Outstanding	6.910M shares	3.790M shares	19.00M shares
Diluted Shares Outstanding		3.790M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.83M	$51.83M	$18.82M
YoY Change	175.39%	35.77%	-69.88%
Cash & Equivalents	$51.83M	$51.83M	$18.82M
Short-Term Investments			$0.00
Other Short-Term Assets	$553.0K	$17.13M	$59.00K
YoY Change	837.29%	610.07%	-99.19%
Inventory
Prepaid Expenses	$949.0K		$245.0K
Receivables
Other Receivables
Total Short-Term Assets	$68.96M	$68.96M	$19.83M
YoY Change	247.86%	68.61%	-72.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.113M	$4.164M	$1.110M
YoY Change	0.27%	93.05%	-66.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$111.0K	$111.0K	$51.00K
YoY Change	117.65%	-68.38%	-89.94%
Total Long-Term Assets	$4.275M	$4.275M	$3.038M
YoY Change	40.72%	70.45%	-20.84%
TOTAL ASSETS
Total Short-Term Assets	$68.96M	$68.96M	$19.83M
Total Long-Term Assets	$4.275M	$4.275M	$3.038M
Total Assets	$73.24M	$73.24M	$22.86M
YoY Change	220.33%	68.72%	-69.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$991.0K	$991.0K	$1.071M
YoY Change	-7.47%	-33.31%	-28.36%
Accrued Expenses	$1.589M	$4.035M	$665.0K
YoY Change	138.95%	-35.56%	-92.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$239.0K
YoY Change			14.9%
Total Short-Term Liabilities	$20.03M	$20.03M	$3.222M
YoY Change	521.54%	150.73%	-74.27%
LONG-TERM LIABILITIES
Long-Term Debt	$15.07M	$15.07M	$61.00K
YoY Change	24603.28%	24603.28%	-63.69%
Other Long-Term Liabilities	$2.026M	$2.026M	$0.00
YoY Change		23.91%	-100.0%
Total Long-Term Liabilities	$15.07M	$17.10M	$61.00K
YoY Change	24603.28%	907.96%	-66.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.03M	$20.03M	$3.222M
Total Long-Term Liabilities	$15.07M	$17.10M	$61.00K
Total Liabilities	$37.12M	$37.12M	$4.949M
YoY Change	650.07%	258.62%	-67.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$100.1M		-$71.76M
YoY Change	39.44%		-65.61%
Common Stock	$7.000K		$1.000K
YoY Change	600.0%		-94.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.12M	$36.12M	-$68.79M
YoY Change
Total Liabilities & Shareholders Equity	$73.24M	$73.24M	$22.86M
YoY Change	220.33%	68.72%	-69.5%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$28.30M	-$28.30M	-$7.362M
YoY Change	284.43%	47.34%	-42.03%
Depreciation, Depletion And Amortization	$102.0K	$374.0K	$37.00K
YoY Change	175.68%	10.32%	-26.0%
Cash From Operating Activities	-$7.985M	-$25.96M	-$5.303M
YoY Change	50.58%	36.49%	-54.64%
INVESTING ACTIVITIES
Capital Expenditures	-$27.00K	$135.0K	$0.00
YoY Change		170.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$38.00K	$0.00
YoY Change
Cash From Investing Activities	-$27.00K	-$97.00K	$0.00
YoY Change		1516.67%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$33.43M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.000K	$59.06M	-64.00K
YoY Change	-85.94%	70.71%	-100.24%
NET CHANGE
Cash From Operating Activities	-7.985M	-$25.96M	-5.303M
Cash From Investing Activities	-27.00K	-$97.00K	0.000
Cash From Financing Activities	-9.000K	$59.06M	-64.00K
Net Change In Cash	-8.021M	$33.01M	-5.367M
YoY Change	49.45%	-232.81%	-135.45%
FREE CASH FLOW
Cash From Operating Activities	-$7.985M	-$25.96M	-$5.303M
Capital Expenditures	-$27.00K	$135.0K	$0.00
Free Cash Flow	-$7.958M	-$26.09M	-$5.303M
YoY Change	50.07%	36.84%	-54.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35890
CY2021	dei	Entity Registrant Name EntityRegistrantName	Tempest Therapeutics, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1472564
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court,
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7173094	shares
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 275
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021	dei	City Area Code CityAreaCode	(415)
CY2021	dei	Local Phone Number LocalPhoneNumber	798-8589
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	TPST
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	us-gaap	Assets Current AssetsCurrent	19825000	USD
CY2021Q2	dei	Entity Public Float EntityPublicFloat	74200000	USD
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2020	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Grand Rapids, Michigan
CY2020	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2020	dei	Auditor Location AuditorLocation	San Francisco, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51829000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18820000	USD
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	USD
CY2020Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1005000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	68963000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1110000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3051000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1877000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51000	USD
CY2021Q4	us-gaap	Assets Assets	73238000	USD
CY2020Q4	us-gaap	Assets Assets	22863000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	991000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1071000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	665000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1442000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	712000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	912000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	695000	USD
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	92000	USD
CY2020Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	0	USD
CY2021Q4	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	0	USD
CY2020Q4	tpst	Early Option Exercise Liability EarlyOptionExerciseLiability	79000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20026000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3222000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	756000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1727000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	37121000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	4949000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	86707000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	196000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6910324	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	527265	shares
CY2021Q4	tpst	Common Stock Shares Subject To Repurchase Shares CommonStockSharesSubjectToRepurchaseShares	0	shares
CY2020Q4	tpst	Common Stock Shares Subject To Repurchase Shares CommonStockSharesSubjectToRepurchaseShares	28996	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136173000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2967000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100063000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71761000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36117000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-68793000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73238000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22863000	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17166000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14389000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9820000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4909000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-26986000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-19298000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1282000	USD
CY2020	us-gaap	Interest Expense InterestExpense	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	90000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1316000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	90000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-28302000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-19208000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.47
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.47
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-41.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-41.03
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3790303	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3790303	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	468161	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	468161	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-50364000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	USD
CY2020	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	258000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	453000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19208000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-68793000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	139000	USD
CY2021	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	133000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	86707000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	33474000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1105000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-6420000	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18001000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	73000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28302000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36117000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-28302000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-19208000	USD
CY2021	us-gaap	Depreciation Depreciation	374000	USD
CY2020	us-gaap	Depreciation Depreciation	339000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1105000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	453000	USD
CY2021	tpst	Noncash Lease Expense NoncashLeaseExpense	896000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	135000	USD
CY2020	tpst	Noncash Lease Expense NoncashLeaseExpense	476000	USD
CY2021	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	583000	USD
CY2020	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	-6000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	179000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	367000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-209000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-574000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	723000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-205000	USD
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	92000	USD
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1040000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	75000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25957000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19017000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000	USD
CY2020	tpst	Proceeds From Cash Acquired In Connection With Reverse Recapitalization ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization	0	USD
CY2021	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	-6420000	USD
CY2021	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	38000	USD
CY2020	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	44000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-97000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6000	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	35000000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33425000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2021	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	95000	USD
CY2020	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	USD
CY2021	tpst	Proceeds From Cash Acquired In Connection With Reverse Recapitalization ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization	17045000	USD
CY2020	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	0	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	69000	USD
CY2021	tpst	Payments For Repurchase Of Unvested Options PaymentsForRepurchaseOfUnvestedOptions	0	USD
CY2020	tpst	Payments For Repurchase Of Unvested Options PaymentsForRepurchaseOfUnvestedOptions	1000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59063000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34599000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	33009000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	15576000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3244000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51829000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	953000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	78000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2021	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	136000	USD
CY2020	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	258000	USD
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	34000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	49000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000000.0	USD
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5365899	shares
CY2021Q2	tpst	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0322
CY2021	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2021	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span>
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company’s cash and money market fund are deposited in accounts with a major financial institution, and amounts may exceed federally insured limits. Management believes that the Company is not </span>exposed to significant credit risk due to the financial strength of the depository institution in which the cash and money market fund are held. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.
CY2021Q2	tpst	Note Receivable Related Party Forgiven NoteReceivableRelatedPartyForgiven	278000	USD
CY2021Q4	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	0	USD
CY2020Q4	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	260000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	949000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	245000	USD
CY2021Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	632000	USD
CY2020Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	441000	USD
CY2021Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	260000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	553000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	59000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1005000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1937000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1566000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	456000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1110000	USD
CY2021	us-gaap	Depreciation Depreciation	374000	USD
CY2020	us-gaap	Depreciation Depreciation	339000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	441000	USD
CY2021Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	841000	USD
CY2020Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	224000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	665000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y4M24D
CY2021Q4	tpst	Number Of Non Cancelable Operating Lease Agreements NumberOfNonCancelableOperatingLeaseAgreements	2	lease
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1603000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1647000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	443000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3693000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	225000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3468000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1442000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	USD
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15069000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	114686731	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	USD
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5365899	shares
CY2021Q2	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	403109	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	264924	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.81
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	224490	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.90
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14406	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.76
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	22843	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.92
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
CY2021	tpst	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod	177591	shares
CY2021	tpst	Share Based Compensation Arrangements By Share Based Payment Award Optionsassumed In Reverse Recapitalization In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice	179.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	307529	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.78
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	33127	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	113521	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	115.72
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62820	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	790476	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y6M10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	32.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	62820	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	339921	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	60.29
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	42790	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1105000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	453000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5906000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4033000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3887000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1799000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9154000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6395000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	767000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	604000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1366000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	37000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	40000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	4000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	125111000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23943000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16670000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4597000	USD
CY2021Q4	tpst	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization	1094000	USD
CY2020Q4	tpst	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization	78000	USD
CY2021Q4	tpst	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1027000	USD
CY2020Q4	tpst	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	714000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3784000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	254000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	254000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	204000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	147940000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29790000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	146933000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29073000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1007000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	717000	USD
CY2021Q4	tpst	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	903000	USD
CY2020Q4	tpst	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	550000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	104000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	167000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1007000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	717000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	tpst	Deferred Tax Assets And Valuation Allowance Deferred Tax Asset Period Increase Decrease Amount DeferredTaxAssetsAndValuationAllowanceDeferredTaxAssetPeriodIncreaseDecreaseAmount	117900000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	452400000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	394100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	80900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	80300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1280000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1080000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2767000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	246000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4293000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1280000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-28302000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19208000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	3799392	shares
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	521146	shares
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	9089	shares
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	52985	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3790303	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3790303	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	468161	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	468161	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.47
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.47
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-41.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-41.03
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	796673	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4174075	shares

Files In Submission

Name	View Source	Status
eyconsentexhibit231.htm	Edgar Link	pending
0001628280-22-007717-index-headers.html	Edgar Link	pending
0001628280-22-007717-index.html	Edgar Link	pending
0001628280-22-007717.txt	Edgar Link	pending
0001628280-22-007717-xbrl.zip	Edgar Link	pending
dtconsentexhibit232.htm	Edgar Link	pending
exhibit3111.htm	Edgar Link	pending
exhibit3121.htm	Edgar Link	pending
exhibit3211.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tempest-2017eipxformofst.htm	Edgar Link	pending
tempest-2017eipxformofst001.jpg	Edgar Link	pending
tempest-2017eipxformofst002.jpg	Edgar Link	pending
tempest-2017eipxformofst003.jpg	Edgar Link	pending
tempest-2017eipxformofst004.jpg	Edgar Link	pending
tempest-2017eipxformofst005.jpg	Edgar Link	pending
tempest-2017eipxformofst006.jpg	Edgar Link	pending
tempest-2017eipxformofst007.jpg	Edgar Link	pending
tempest-2017eipxformofst008.jpg	Edgar Link	pending
tempest-2017eipxformofst009.jpg	Edgar Link	pending
tempest-2017eipxformofst010.jpg	Edgar Link	pending
tempest-2017eipxformofst011.jpg	Edgar Link	pending
tempest-2017eipxformofst012.jpg	Edgar Link	pending
tpst-20211231.htm	Edgar Link	pending
tpst-20211231.xsd	Edgar Link	pending
tpst-20211231_cal.xml	Edgar Link	unprocessable
tpst-20211231_def.xml	Edgar Link	unprocessable
tpst-20211231_g1.jpg	Edgar Link	pending
tpst-20211231_g2.jpg	Edgar Link	pending
tpst-20211231_g3.jpg	Edgar Link	pending
tpst-20211231_g4.jpg	Edgar Link	pending
tpst-20211231_g5.jpg	Edgar Link	pending
tpst-20211231_g6.jpg	Edgar Link	pending
tpst-20211231_g7.jpg	Edgar Link	pending
tpst-20211231_g8.jpg	Edgar Link	pending
tpst-20211231_g9.jpg	Edgar Link	pending
tpst-20211231_htm.xml	Edgar Link	completed
tpst-20211231_lab.xml	Edgar Link	unprocessable
tpst-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2021 Q4 Form 10-K Financial Statement

#000162828022007717 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2021 Q4 Form 10-K Financial Statement

#000162828022007717 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst